The Relationship of Streptolysin S Inhibitor to Phospholipids in the Serum of Human Beings and Experimental Animals

The Use of Hemolysin Inhibition in the Study of Experimental And Clinical Hyperlipemia: THE NON-SPECIFIC INHIBITION OF STREPTOLYSIN O BY SERUM LIPOPROTEINS1

“…Streptolysin S has been shown to be inhibited by serum lipoproteins. This inhibition may be varied by measures which alter the native state of these proteins or by diseases which are associated with disturbances in lipid metabolism (4)(5)(6)(7)(8). Also, the inhibition of saponin hemolysis by whole plasma is not a simple function of the concentration of its lipid components.…”

Opacification Domain of Serum Opacity Factor Inhibits Beta-Hemolysis and Contributes to Virulence of Streptococcus pyogenes

“…Since the opacification domain of SOF interacts readily with HDL, it is possible that SOF depletes HDL in the sheep blood agar, destabilizes SLS activity, and thereby reduces SLS-mediated beta-hemolysis. In this context, SLS hemolytic activity can be inhibited by phospholipids ( 21 , 22 ). Since SOF-HDL interaction results in the production of phospholipid-rich neo-HDL ( 4 , 8 ), it is also possible that the products of SOF-HDL interaction inhibit SLS hemolytic activity.…”